Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol-Myers Squibb Co.

www.bms.com

Latest From Bristol-Myers Squibb Co.

Keeping Track, Oncology Edition: Biologic Breakthroughs And BLAs

The latest oncology development news and highlights from our US FDA Performance Tracker.

US FDA Performance Tracker Cancer

Kite Readies A Second CAR-T For Filing As CD19 Competition Grows

The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year. 

Clinical Trials Cancer

Immuno-Oncology Continues To Draw Pharma Companies To The Deal Table

Immuno-oncology development trends are revealed through an analysis of deals between cancer drug developers over the past five years.

BioPharmaceutical Deals

Bristol’s CAR-T Strategy Comes Into Focus With Two Near-Term Filings

In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.

Clinical Trials ImmunoOncology
See All

Company Information

UsernamePublicRestriction

Register